Symbols / SMMT
SMMT Chart
About
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 12.00B |
| Enterprise Value | 11.74B | Income | -921.62M | Sales | — |
| Book/sh | 0.26 | Cash/sh | 0.32 | Dividend Yield | — |
| Payout | 0.00% | Employees | 159 | IPO | — |
| P/E | — | Forward P/E | -13.70 | PEG | — |
| P/S | — | P/B | 62.48 | P/C | — |
| EV/EBITDA | -12.56 | EV/Sales | — | Quick Ratio | 3.67 |
| Current Ratio | 3.80 | Debt/Eq | 2.82 | LT Debt/Eq | — |
| EPS (ttm) | -1.25 | EPS next Y | -1.18 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-04-30 | ROA | -152.88% |
| ROE | -292.49% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 744.44M |
| Shs Float | 125.16M | Short Float | 31.21% | Short Ratio | 12.11 |
| Short Interest | — | 52W High | 36.91 | 52W Low | 13.83 |
| Beta | -1.43 | Avg Volume | 2.64M | Volume | 2.53M |
| Target Price | $31.77 | Recom | Buy | Prev Close | $16.09 |
| Price | $16.12 | Change | 0.19% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$31.77
Mean price target
2. Current target
$16.12
Latest analyst target
3. DCF / Fair value
$1.78
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$16.12
Low
$12.01
High
$42.02
Mean
$31.77
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-24 | main | HC Wainwright & Co. | Buy → Buy | $30 |
| 2026-02-02 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2026-01-30 | reit | Citizens | Market Outperform → Market Outperform | $40 |
| 2025-12-17 | up | Barclays | Underweight → Equal-Weight | $18 |
| 2025-11-18 | init | Wolfe Research | — → Peer Perform | — |
| 2025-10-22 | reit | Guggenheim | Buy → Buy | $40 |
| 2025-10-21 | main | Barclays | Underweight → Underweight | $16 |
| 2025-10-21 | main | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-10-20 | main | Citigroup | Buy → Buy | $40 |
| 2025-10-20 | reit | JMP Securities | Market Outperform → Market Outperform | $40 |
| 2025-09-17 | init | Barclays | — → Underweight | $13 |
| 2025-09-16 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-09-08 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2025-09-08 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-09-04 | init | Guggenheim | — → Buy | $40 |
| 2025-09-03 | reit | JMP Securities | Market Outperform → Market Outperform | $40 |
| 2025-09-02 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-08-27 | main | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-08-19 | reit | JMP Securities | Market Outperform → Market Outperform | $40 |
| 2025-08-19 | init | Piper Sandler | — → Neutral | $21 |
- Assessing Summit Therapeutics (SMMT) Valuation After Recent Share Price Swings - simplywall.st ue, 24 Feb 2026 13
- SMMT: Analyst Lowers Price Target to $30, Maintains Buy Rating | SMMT Stock News - GuruFocus ue, 24 Feb 2026 12
- Summit Therapeutics posts $1.08B loss, FDA accepts lung cancer BLA - Stock Titan Mon, 23 Feb 2026 21
- Summit Therapeutics (SMMT) Is Up 7.6% After Steep Losses And New US$102 Million Shelf Registration - Has The Bull Case Changed? - Yahoo! Finance Canada ue, 24 Feb 2026 10
- SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus - TradingView ue, 24 Feb 2026 16
- $SMMT stock is down 5% today. Here's what we see in our data. - Quiver Quantitative Fri, 23 Jan 2026 08
- 2 Stocks That Could Soar This Year - The Motley Fool Sat, 31 Jan 2026 08
- Summit Therapeutics Reports 2025 Results, Advances Ivonescimab Programs - TipRanks Mon, 23 Feb 2026 21
- 20 new Summit hires get 10-year options on 257K shares - Stock Titan Fri, 30 Jan 2026 08
- SMMT: Net loss surged to $1.08B as ivonescimab advanced in Phase III and FDA review, with major new funding - TradingView Mon, 23 Feb 2026 21
- Is Summit Therapeutics (SMMT) Pricing Reflecting Its Recent Share Price Pullback Accurately - Yahoo Finance Sun, 08 Feb 2026 08
- Summit Therapeutics (SMMT) Set for Potential Upside Ahead of Key Data Release - GuruFocus ue, 24 Feb 2026 11
- Summit Therapeutics (NASDAQ: SMMT) posts 2025 loss but ends year with $713M cash - Stock Titan Mon, 23 Feb 2026 21
- Is Summit Therapeutics Inc. (SMMT) One of the Most Oversold NASDAQ Stocks to Invest In? - Yahoo Finance hu, 12 Feb 2026 08
- Summit sets Feb. 23 webcast to review Q4 and full-year 2025 results - Stock Titan ue, 17 Feb 2026 22
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 14247597 | 266999968 | — | Stock Award(Grant) at price 18.74 per share. | DUGGAN ROBERT WILLIAM | Chief Executive Officer | — | 2025-10-21 00:00:00 | D/I |
| 1 | 26680 | 499983 | — | Purchase at price 18.74 per share. | DUGGAN ROBERT WILLIAM | Chief Executive Officer | — | 2025-10-21 00:00:00 | I |
| 2 | 14247597 | 266999968 | — | Stock Award(Grant) at price 18.74 per share. | ZANGANEH MAHKAM | Chief Executive Officer | — | 2025-10-21 00:00:00 | I |
| 3 | 26680 | 499983 | — | Purchase at price 18.74 per share. | ZANGANEH MAHKAM | Chief Executive Officer | — | 2025-10-21 00:00:00 | I |
| 4 | 53361 | 999985 | — | Stock Award(Grant) at price 18.74 per share. | SONI MANMEET SINGH | Chief Operating Officer | — | 2025-10-21 00:00:00 | D |
| 5 | 26680 | 499983 | — | Stock Award(Grant) at price 18.74 per share. | ANAND BHASKAR | Officer | — | 2025-10-21 00:00:00 | D |
| 6 | 533617 | 9999983 | — | Purchase at price 18.74 per share. | XIA YU | Director | — | 2025-10-21 00:00:00 | I |
| 7 | 338394 | 5984756 | — | Purchase at price 17.68 - 18.07 per share. | DUGGAN ROBERT WILLIAM | Chief Executive Officer | — | 2025-09-11 00:00:00 | D |
| 8 | 338394 | 5984756 | — | Purchase at price 17.68 - 18.07 per share. | ZANGANEH MAHKAM | Chief Executive Officer | — | 2025-09-11 00:00:00 | I |
| 9 | 74545 | 196799 | — | Conversion of Exercise of derivative security at price 2.64 per share. | DUGGAN ROBERT WILLIAM | Chief Executive Officer | — | 2025-05-30 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -197.41M | -78.42M | -60.54M | -83.77M |
| TotalUnusualItems | -15.10M | -519.88M | -12.58M | -2.13M |
| TotalUnusualItemsExcludingGoodwill | -15.10M | -519.88M | -12.58M | -2.13M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -221.31M | -614.93M | -78.78M | -88.60M |
| ReconciledDepreciation | 89.00K | 198.00K | 1.26M | 2.46M |
| EBITDA | -212.51M | -598.30M | -73.12M | -85.91M |
| EBIT | -212.60M | -598.50M | -74.38M | -88.36M |
| NetInterestIncome | 4.78M | -6.06M | -2.89M | -242.00K |
| InterestExpense | 8.69M | 16.46M | 4.40M | 242.00K |
| InterestIncome | 13.47M | 10.40M | 1.51M | 0.00 |
| NormalizedIncome | -206.21M | -95.05M | -66.20M | -86.47M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -221.31M | -614.93M | -78.78M | -88.60M |
| TotalExpenses | 210.96M | 88.77M | 64.33M | 87.98M |
| TotalOperatingIncomeAsReported | -226.00M | -609.65M | -72.09M | -86.19M |
| DilutedAverageShares | 718.54M | 619.65M | 193.34M | 92.29M |
| BasicAverageShares | 718.54M | 619.65M | 193.34M | 92.29M |
| DilutedEPS | -0.31 | -0.99 | -0.41 | -0.96 |
| BasicEPS | -0.31 | -0.99 | -0.41 | -0.96 |
| DilutedNIAvailtoComStockholders | -221.31M | -614.93M | -78.78M | -88.60M |
| NetIncomeCommonStockholders | -221.31M | -614.93M | -78.78M | -88.60M |
| NetIncome | -221.31M | -614.93M | -78.78M | -88.60M |
| NetIncomeIncludingNoncontrollingInterests | -221.29M | -614.96M | -78.78M | -88.60M |
| NetIncomeContinuousOperations | -221.29M | -614.96M | -78.78M | -88.60M |
| TaxProvision | 0.00 | |||
| PretaxIncome | -221.29M | -614.96M | -78.78M | -88.60M |
| OtherIncomeExpense | -15.10M | -520.13M | -12.27M | -2.17M |
| OtherNonOperatingIncomeExpenses | -252.00K | 304.00K | -39.00K | |
| SpecialIncomeCharges | -15.01M | -520.91M | -8.47M | 0.00 |
| OtherSpecialCharges | 15.01M | 520.91M | ||
| ImpairmentOfCapitalAssets | 0.00 | 0.00 | 8.47M | 0.00 |
| GainOnSaleOfSecurity | -97.00K | 1.03M | -4.11M | -2.13M |
| NetNonOperatingInterestIncomeExpense | 4.78M | -6.06M | -2.89M | -242.00K |
| InterestExpenseNonOperating | 8.69M | 16.46M | 4.40M | 242.00K |
| InterestIncomeNonOperating | 13.47M | 10.40M | 1.51M | 0.00 |
| OperatingIncome | -210.96M | -88.77M | -63.62M | -86.17M |
| OperatingExpense | 210.96M | 88.77M | 64.33M | 87.98M |
| OtherOperatingExpenses | -55.00K | -9.89M | -5.76M | |
| OtherTaxes | -313.00K | -946.00K | -4.52M | -15.21M |
| ResearchAndDevelopment | 150.78M | 59.47M | 52.00M | 85.35M |
| SellingGeneralAndAdministration | 60.50M | 30.30M | 26.74M | 23.60M |
| GeneralAndAdministrativeExpense | 60.50M | 30.30M | 26.74M | 23.60M |
| OtherGandA | 10.80M | 10.50M | 26.74M | 7.00M |
| SalariesAndWages | 49.70M | 19.80M | 19.10M | 16.60M |
| TotalRevenue | 0.00 | 0.00 | 705.00K | 1.81M |
| OperatingRevenue | 0.00 | 0.00 | 705.00K | 1.81M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 737.63M | 701.66M | 211.09M | 98.04M |
| ShareIssued | 737.63M | 701.66M | 211.09M | 98.04M |
| NetDebt | 28.57M | 165.70M | ||
| TotalDebt | 7.22M | 106.10M | 518.76M | 2.78M |
| TangibleBookValue | 386.88M | 75.80M | 124.86M | 70.88M |
| InvestedCapital | 388.75M | 177.69M | 640.96M | 83.28M |
| WorkingCapital | 382.02M | 169.31M | 617.93M | 71.69M |
| NetTangibleAssets | 386.88M | 75.80M | 124.86M | 70.88M |
| CapitalLeaseObligations | 7.22M | 6.10M | 4.45M | 2.78M |
| CommonStockEquity | 388.75M | 77.69M | 126.65M | 83.28M |
| TotalCapitalization | 388.75M | 177.69M | 621.19M | 83.28M |
| TotalEquityGrossMinorityInterest | 388.75M | 77.69M | 126.65M | 83.28M |
| StockholdersEquity | 388.75M | 77.69M | 126.65M | 83.28M |
| GainsLossesNotAffectingRetainedEarnings | -2.29M | -2.45M | -1.89M | -2.20M |
| OtherEquityAdjustments | -2.29M | -2.45M | -1.89M | -2.20M |
| RetainedEarnings | -1.21B | -993.26M | -378.33M | -299.55M |
| AdditionalPaidInCapital | 1.60B | 1.07B | 504.77M | 384.05M |
| CapitalStock | 7.38M | 7.02M | 2.11M | 980.00K |
| CommonStock | 7.38M | 7.02M | 2.11M | 980.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 46.81M | 125.26M | 537.51M | 30.09M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 5.08M | 104.85M | 498.73M | 4.47M |
| OtherNonCurrentLiabilities | 1.63M | 1.56M | 1.43M | 2.78M |
| NonCurrentDeferredLiabilities | 0.00 | |||
| NonCurrentDeferredRevenue | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 3.45M | 103.29M | 497.30M | 1.69M |
| LongTermCapitalLeaseObligation | 3.45M | 3.29M | 2.76M | 1.69M |
| LongTermDebt | 100.00M | 494.54M | ||
| CurrentLiabilities | 41.73M | 20.41M | 38.78M | 25.62M |
| OtherCurrentLiabilities | 1.80M | 717.00K | 662.00K | 897.00K |
| CurrentDeferredLiabilities | 0.00 | 7.94M | ||
| CurrentDeferredRevenue | 0.00 | 7.94M | ||
| CurrentDebtAndCapitalLeaseObligation | 3.77M | 2.81M | 21.46M | 1.09M |
| CurrentCapitalLeaseObligation | 3.77M | 2.81M | 1.69M | 1.09M |
| CurrentDebt | 19.77M | |||
| CurrentNotesPayable | 0.00 | 19.77M | 0.00 | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 11.98M | 5.43M | 5.64M | 4.12M |
| PayablesAndAccruedExpenses | 24.19M | 11.45M | 11.02M | 11.57M |
| CurrentAccruedExpenses | 19.55M | 8.78M | 10.66M | 7.20M |
| Payables | 4.64M | 2.67M | 355.00K | 4.37M |
| AccountsPayable | 4.64M | 2.67M | 355.00K | 4.37M |
| TotalAssets | 435.56M | 202.95M | 664.17M | 113.37M |
| TotalNonCurrentAssets | 11.81M | 13.24M | 7.46M | 16.06M |
| OtherNonCurrentAssets | 1.85M | 4.32M | 577.00K | 170.00K |
| NonCurrentAccountsReceivable | 698.00K | 959.00K | ||
| GoodwillAndOtherIntangibleAssets | 1.86M | 1.89M | 1.80M | 12.41M |
| OtherIntangibleAssets | 10.40M | |||
| Goodwill | 1.86M | 1.89M | 1.80M | 2.01M |
| NetPPE | 7.40M | 6.06M | 5.08M | 3.48M |
| AccumulatedDepreciation | -1.12M | -1.04M | -1.30M | -1.04M |
| GrossPPE | 8.52M | 7.11M | 6.38M | 4.52M |
| Leases | 323.00K | 328.00K | 809.00K | 365.00K |
| OtherProperties | 7.17M | 5.88M | 4.68M | 3.34M |
| MachineryFurnitureEquipment | 1.03M | 896.00K | 889.00K | 819.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 423.75M | 189.71M | 656.71M | 97.31M |
| OtherCurrentAssets | 10.52M | 2.62M | 486.00K | 1.20M |
| RestrictedCash | 325.00K | 0.00 | 300.00M | 0.00 |
| PrepaidAssets | 2.44M | 1.50M | 7.16M | |
| Receivables | 557.00K | 848.00K | 6.12M | 24.32M |
| OtherReceivables | 1.50M | 7.16M | ||
| TaxesReceivable | 557.00K | 848.00K | 5.77M | 15.70M |
| AccountsReceivable | 0.00 | 349.00K | 1.46M | |
| CashCashEquivalentsAndShortTermInvestments | 412.35M | 186.24M | 348.61M | 71.79M |
| OtherShortTermInvestments | 307.49M | 114.82M | 0.00 | |
| CashAndCashEquivalents | 104.86M | 71.42M | 348.61M | 71.79M |
| CashEquivalents | 88.60M | 60.36M | 286.51M | |
| CashFinancial | 16.26M | 11.07M | 62.09M | 71.79M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -142.25M | -76.89M | -42.21M | -72.89M |
| RepaymentOfDebt | -100.00M | -24.69M | -25.00M | -110.00M |
| IssuanceOfDebt | 0.00 | 0.00 | 545.00M | 110.00M |
| IssuanceOfCapitalStock | 477.89M | 109.69M | 100.00M | 75.00M |
| CapitalExpenditure | -139.00K | -128.00K | -624.00K | -306.00K |
| InterestPaidSupplementalData | 8.81M | 10.65M | 434.00K | 85.00K |
| IncomeTaxPaidSupplementalData | 0.00 | 52.00K | 0.00 | 7.00K |
| EndCashPosition | 105.19M | 71.42M | 648.61M | 71.79M |
| BeginningCashPosition | 71.42M | 648.61M | 71.79M | 66.42M |
| EffectOfExchangeRateChanges | -18.00K | 839.00K | -1.22M | 351.00K |
| ChangesInCash | 33.78M | -578.02M | 578.04M | 5.02M |
| FinancingCashFlow | 381.23M | 86.51M | 620.24M | 77.92M |
| CashFlowFromContinuingFinancingActivities | 381.23M | 86.51M | 620.24M | 77.92M |
| NetOtherFinancingCharges | -619.00K | -155.00K | -172.00K | |
| ProceedsFromStockOptionExercised | 3.33M | 2.13M | 399.00K | 3.09M |
| NetCommonStockIssuance | 477.89M | 109.69M | 100.00M | 75.00M |
| CommonStockIssuance | 477.89M | 109.69M | 100.00M | 75.00M |
| NetIssuancePaymentsOfDebt | -100.00M | -24.69M | 520.00M | 0.00 |
| NetLongTermDebtIssuance | -100.00M | -24.69M | 520.00M | 0.00 |
| LongTermDebtPayments | -100.00M | -24.69M | -25.00M | -110.00M |
| LongTermDebtIssuance | 0.00 | 0.00 | 545.00M | 110.00M |
| InvestingCashFlow | -205.34M | -587.77M | -624.00K | -306.00K |
| CashFlowFromContinuingInvestingActivities | -205.34M | -587.77M | -624.00K | -306.00K |
| NetOtherInvestingChanges | -15.01M | -475.01M | ||
| NetInvestmentPurchaseAndSale | -190.19M | -112.86M | 0.00 | |
| SaleOfInvestment | 489.84M | 208.16M | 0.00 | |
| PurchaseOfInvestment | -680.03M | -321.02M | 0.00 | |
| NetPPEPurchaseAndSale | -139.00K | 98.00K | -624.00K | -306.00K |
| SaleOfPPE | 0.00 | 226.00K | 0.00 | |
| PurchaseOfPPE | -139.00K | -128.00K | -624.00K | -306.00K |
| OperatingCashFlow | -142.11M | -76.76M | -41.58M | -72.59M |
| CashFlowFromContinuingOperatingActivities | -142.11M | -76.76M | -41.58M | -72.59M |
| ChangeInWorkingCapital | 15.48M | -516.00K | 9.87M | -67.00K |
| ChangeInOtherWorkingCapital | -167.00K | -359.00K | -7.13M | -813.00K |
| ChangeInOtherCurrentLiabilities | 95.00K | 0.00 | 0.00 | -1.07M |
| ChangeInOtherCurrentAssets | 2.47M | -3.42M | 215.00K | 104.00K |
| ChangeInPayablesAndAccruedExpense | 20.45M | -349.00K | 2.26M | 6.52M |
| ChangeInAccruedExpense | 18.44M | -2.61M | 6.39M | 8.23M |
| ChangeInPayable | 2.02M | 2.26M | -4.13M | -1.71M |
| ChangeInAccountPayable | 2.02M | 2.26M | -4.13M | -1.71M |
| ChangeInPrepaidAssets | -7.91M | -914.00K | 5.11M | 2.35M |
| ChangeInReceivables | 535.00K | 4.53M | 9.41M | -7.15M |
| ChangesInAccountReceivables | 0.00 | 359.00K | 975.00K | -1.14M |
| OtherNonCashItems | 15.01M | 527.17M | 3.04M | 497.00K |
| StockBasedCompensation | 50.98M | 14.11M | 11.95M | 12.80M |
| AssetImpairmentCharge | 0.00 | 474.00K | 8.47M | 0.00 |
| AmortizationOfSecurities | -2.58M | -1.92M | 0.00 | |
| DepreciationAmortizationDepletion | 89.00K | 198.00K | 1.26M | 2.46M |
| DepreciationAndAmortization | 89.00K | 198.00K | 1.26M | 2.46M |
| AmortizationCashFlow | 0.00 | 0.00 | 914.00K | 1.02M |
| AmortizationOfIntangibles | 0.00 | 0.00 | 914.00K | 1.02M |
| Depreciation | 89.00K | 198.00K | 349.00K | 1.44M |
| OperatingGainsLosses | 229.00K | -1.34M | 2.62M | 326.00K |
| NetForeignCurrencyExchangeGainLoss | 229.00K | -1.23M | 2.62M | 326.00K |
| GainLossOnSaleOfPPE | -109.00K | 0.00 | ||
| NetIncomeFromContinuingOperations | -221.31M | -614.93M | -78.78M | -88.60M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SMMT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|